alzhub.org
Get help now — free helplines

You can call any of these for free. You do not need a diagnosis, an appointment, or a crisis to call — questions and plain exhaustion are reasons enough.

  • Alzheimer's Association 24/7 Helpline 800-272-3900 24 hours a day, 365 days a year Free, confidential support and information for people with dementia, caregivers, families and the public. Master's-level clinicians. Also Spanish.
  • 988 Suicide & Crisis Lifeline 988 24/7 Call or text 988, or chat at 988lifeline.org. For anyone in emotional distress or a mental-health crisis, including caregivers.
  • Alzheimer's Foundation of America (AFA) Helpline 866-232-8484 9:00 am - 9:00 pm ET, seven days a week Licensed social workers providing support, info and referrals. Also text message and web chat. Text: 646-586-5283

In a medical emergency, call 911. More numbers, and what each line does, on the help page.

Research

28,180 Alzheimer's and dementia studies in plain English, each scored out of 100.

Find studies

Showing 376–400 of 571 studies · free to read · tagged Digital Tools (page 16 of 23) · 28,180 in the whole library · How the 0–100 score works

Download bibliography of the first 500 of these studies, in this order: BibTeX (.bib) · RIS (.ris)

Browse by subject, author or institution

Each number is how many studies that link shows, with your other filters kept.

Subjects

Authors

Names as each record prints them; the same person can appear under two spellings.

Institutions

From OpenAlex; 13,658 studies have no institution on record and are not counted here.

A note on reading research. One study is rarely the final word.

We try to note the size of a study, whether it was in humans or animals, and how early-stage the finding is. If a summary here doesn't make that clear, treat it with extra caution and check the original source.

Retromer Proteins Reduced in Down Syndrome and the Dp16 Model: Impact of APP Dose and Preclinical Studies of a γ-Secretase Modulator

✓ Peer-reviewed alzhub usefulness score 41 out of 100. Annals of neurology 2023-04-29

Our studies point to increased APP gene dose as a compromising retromer function in DS and suggest a causal role for Aβ42 and Aβ40. 2 key findings →

Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

The roles of amyloid precursor protein (APP) in neurogenesis: Implications to pathogenesis and therapy of Alzheimer disease

✓ Peer-reviewed alzhub usefulness score 41 out of 100. Cell adhesion & migration 2011-07-01

The amyloid-beta (Aβ) peptide is the derivative of amyloid precursor protein (APP) generated through sequential proteolytic processing by β- and γ-secretases. 4 key findings →

Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

BRI2 interacts with amyloid precursor protein (APP) and regulates amyloid beta (Abeta) production

✓ Peer-reviewed alzhub usefulness score 41 out of 100. The Journal of biological chemistry 2005-07-18

Transmembrane proteins BRI2 and amyloid precursor protein (APP) co-localize with amyloid beta (Abeta) lesions in sporadic Alzheimer disease and mutations in both precursor proteins are linked to early-onset familial cases of cerebral amyloidosis associated with dementia and/or cerebral hemorrhage. 4 key findings →

Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

Availability and use of telehealth services among patients with ADRD enrolled in traditional Medicare vs. Medicare advantage during the COVID-19 pandemic

✓ Peer-reviewed alzhub usefulness score 41 out of 100. Frontiers in Public Health 2024-02-27

There were 13,700 beneficiaries with full-year enrollment in MA (6,046) or TM (7,724), 518 with ADRD and 13,252 without ADRD. 5 key findings →

Design: cross-sectional Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

The Rapid Online Cognitive Assessment for the Detection of Neurocognitive Disorder: Open-Label Study

✓ Peer-reviewed alzhub usefulness score 41 out of 100. Journal of Medical Internet Research 2025-06-19

RoCA classifies patients similarly to gold standard paper-based tests, with a receiver operating characteristic area under the curve of 0.81 (95% CI 0.67-0.91; P<.001). 5 key findings →

Design: open-label trial Participants: 35 Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

Transfer deep learning and explainable AI framework for brain tumor and Alzheimer's detection across multiple datasets

✓ Peer-reviewed alzhub usefulness score 41 out of 100. Frontiers in Medicine 2025-06-19

The model achieves accuracy rates of 94% on the brain tumor dataset, 81% on the augmented Alzheimer dataset, and 93% on the third dataset, underscoring its capability to differentiate various neurological conditions. 3 key findings →

Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

Mapping Caregiver Needs to AI Chatbot Design: Strengths and Gaps in Mental Health Support for Alzheimer's and Dementia Caregivers

✓ Peer-reviewed alzhub usefulness score 41 out of 100. ACM Transactions on Computing for Healthcare 2026-03-24

Family caregivers of individuals with Alzheimer’s Disease and Related Dementia (AD/ADRD) face significant emotional and logistical challenges that place them at heightened risk for stress, anxiety, and depression. 2 key findings →

Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

Preliminary efficacy of an online intervention based on Acceptance and Commitment Therapy for family caregivers of people with dementia: a feasibility study

✓ Peer-reviewed alzhub usefulness score 41 out of 100. Cognitive Behaviour Therapy 2025-03-27

With the rising number of dementia cases, supporting family caregivers to maintain their well-being is crucial. 4 key findings →

Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

Leveraging data, technology, and policy to address disparities for persons living with Alzheimer's disease and Alzheimer's disease related dementias

✓ Peer-reviewed alzhub usefulness score 41 out of 100. Alzheimer s & Dementia 2025-04-01

Addressing disparities related to Alzheimer's disease and Alzheimer's disease related dementias (AD/ADRD) is a priority for policymakers, practitioners, and researchers. 5 key findings →

Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

Investigating the Utility of Explainable Artificial Intelligence for Neuroimaging‐Based Dementia Diagnosis and Prognosis

✓ Peer-reviewed alzhub usefulness score 41 out of 100. Human Brain Mapping 2026-02-01

Artificial intelligence and neuroimaging enable accurate dementia prediction but often involve 'black box' models that can be difficult to trust. 5 key findings →

Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

Acceptability of wearable technology for the early detection of dementia-causing diseases: perspectives from the CODEC II cohort

✓ Peer-reviewed alzhub usefulness score 41 out of 100. BMC Digital Health 2025-08-28

= 1), and three caregivers. Five key themes were identified, including ease of use, wearability, usefulness, transparency, and behavioral intention. 5 key findings →

Evidence: moderate

Full summary, score breakdown and related studies → Original source Free full text

Handwriting in Mild Cognitive Impairment: Reliability Assessment and Machine Learning–Based Screening

✓ Peer-reviewed alzhub usefulness score 41 out of 100. JMIR Aging 2025-09-23

The presented results suggest the suitability of ecological handwriting analysis for the all-around monitoring of MCI, from early screening to disease progression evaluation. 4 key findings →

Participants: 57 Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

Alpha-synuclein aggregation induces prominent cellular lipid changes as revealed by Raman spectroscopy and machine learning analysis

✓ Peer-reviewed alzhub usefulness score 41 out of 100. Brain Communications 2025-01-01

HEK293, Neuro2a and SH-SY5Y expressing increased levels of α-synuclein were treated with sonicated α-synuclein pre-formed fibrils, to model seeded aggregation. 1 key finding →

Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

IRMA: Machine learning-based harmonization of $$^{18}$$F-FDG PET brain scans in multi-center studies

✓ Peer-reviewed alzhub usefulness score 41 out of 100. European Journal of Nuclear Medicine and Molecular Imaging 2025-02-18

IRMA can be used to learn and disregard center-specific information in features extracted from brain $$^{18}$$ 18 F-FDG PET scans, while retaining disease-specific information. 2 key findings →

Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

Machine learning diagnosis of mild cognitive impairment using advanced diffusion MRI and CSF biomarkers

✓ Peer-reviewed alzhub usefulness score 41 out of 100. Alzheimer s & Dementia Diagnosis Assessment & Disease Monitoring 2025-07-01

MAP-RTAP (AUC = 0.78) and pTau/Aβ42 (AUC = 0.76) were the best performing individual biomarkers. 4 key findings →

Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

Multicomponent interventions and technologies to reduce the burden of frailty, functional, and cognitive decline: insights from the Age-It Research Program

✓ Peer-reviewed alzhub usefulness score 41 out of 100. The Journals of Gerontology Series B 2025-09-28

The project is expected to generate evidence on the effectiveness, feasibility, and cost-effectiveness of multidomain interventions implemented across diverse real-world settings, including community, hospital, and long-term care. 5 key findings →

Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

Race-Specific Impact of Telehealth Advance Care Planning on Cost of Dementia: A Cost Prediction Study

✓ Peer-reviewed alzhub usefulness score 41 out of 100. International Journal of Environmental Research and Public Health 2025-09-07

Identifying strategies to enhance patient engagement and to control healthcare costs promotes a responsive and efficient healthcare system. 4 key findings →

Participants: 401 Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

Predicting Prodromal Alzheimer's Disease in Subjects with Mild Cognitive Impairment Using Machine Learning Classification of Multimodal Multicenter Diffusion-Tensor and Magnetic Resonance Imaging Data

✓ Peer-reviewed alzhub usefulness score 40 out of 100. Journal of neuroimaging : official journal of the American Society of Neuroimaging 2015-01-28

Our results suggest that DTI data provide better prediction accuracy than GM volume in predementia AD. 3 key findings →

Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

The Evaluation of Telehealth's Impact on Medicare Annual Wellness Visits and Dementia Diagnosis

✓ Peer-reviewed alzhub usefulness score 40 out of 100. Alzheimer s & Dementia 2025-12-01

We found a significant increase in the likelihood of AWV uptake among telehealth adopters by 10.2 percentage points (p <0.001) than non-adopters of telehealth in traditional FFS Medicare plans. 5 key findings →

Design: longitudinal study Evidence: moderate

Full summary, score breakdown and related studies → Original source Free full text

The Evaluation of Telehealth's Impact on Medicare Annual Wellness Visits and Dementia Diagnosis

✓ Peer-reviewed alzhub usefulness score 40 out of 100. Alzheimer s & Dementia 2025-12-01

We found a significant increase in the likelihood of AWV uptake among telehealth adopters by 10.2 percentage points (p <0.001) than non-adopters of telehealth in traditional FFS Medicare plans. 5 key findings →

Design: longitudinal study Evidence: moderate

Full summary, score breakdown and related studies → Original source Free full text

↑ Change the filters

Where “Free full text” comes from

Free full text links and the Full text may need a subscription label come from Unpaywall, Europe PMC and OpenAlex records of free copies, checked 10 Oct 2026. A study with neither is unknown, not paywalled.

How the 0–100 score works — and why some entries are capped

This is alzhub's own score. It is not an official metric, not an impact factor, and no journal, publisher or ranking body endorses it. We built it so that a reader who is not a scientist can tell a landmark trial from a conference abstract without having to already know the difference. Every point comes from one of 20 components, all of them printed on the study itself, so you can disagree with our arithmetic rather than having to trust the total.

  • Journal tier up to 10 pts
  • Journal's citation record up to 4 pts
  • Study design up to 12 pts
  • Strength of evidence up to 5 pts
  • Peer-review validation up to 10 pts
  • How recent up to 5 pts
  • Sample size up to 4 pts
  • Effect reported up to 3 pts
  • Studied in people up to 3 pts
  • Randomised / blinded up to 2 pts
  • Times cited up to 7 pts
  • Citations per year up to 5 pts
  • Impact for its field and year up to 6 pts
  • Cited by studies here up to 6 pts
  • Still being cited up to 4 pts
  • Senior author's track record up to 4 pts
  • Institution's track record up to 3 pts
  • Multi-centre collaboration up to 3 pts
  • Indexed in PubMed up to 2 pts
  • Free to read up to 2 pts

Journals are placed in ordered tiers, never given a numeric impact factor — we could not verify current impact factors from a source we control, and an invented one would be worse than none. Tier 1 is the top-tier general journals (NEJM, The Lancet, JAMA, Nature, Science, Nature Medicine); tier 2 is the leading specialty journals; tier 3 is every other peer-reviewed journal. A separate part scores how much the journal's own papers are cited, which tells the tier-3 journals apart.

Two rules we don't bend. First, we never fill in a missing value: if a record does not state a sample size or a design, that component scores zero, and if we simply have no data for a part, such as a citation count, that part is left out and the study is scored on the parts we could check. The study card says which. Second, anything that is not a peer-reviewed article is capped at 16/100 and carries a warning chip — so a conference abstract or a company press release can never outrank a peer-reviewed paper, no matter how good it looks.

We rank a rigorous null result — a good trial showing that something does not work — above an early positive finding. Someone deciding whether to buy a supplement is served by that, and the rigour is already counted by the design and journal components.

The score is computed from the published data alone and is reproducible: the same file always yields the same numbers.

See the whole rubric drawn out → — four charts covering all 28,180 studies: how the scores are spread and where the cap bites, which of the 20 components the library is strong and weak on, which subjects rest on stronger evidence, and what kinds of study each subject is actually built from.

What this library is — and isn't

This is a large sample of the Alzheimer's literature, not an exhaustive index of it. It holds 28,180 records, built mostly from automated pulls of Europe PMC (61.7% of the library) and OpenAlex (18.1%), plus smaller pulls from PubMed, Crossref and medRxiv. If a study, a drug, or a finding isn't here, that is not evidence it doesn't exist in the literature — it may simply not have been pulled in yet.

1,034 records (3.7% of the library) are not peer-reviewed — 962 of those are preprints posted before any journal review, and the rest are conference abstracts, regulatory notices and reports. Every study card on this page states its status plainly, and the score above is capped for anything that isn't a peer-reviewed article.

See the full, machine-readable breakdown of this library's coverage →

Newest studies, as a dated timeline →    Atom feed